Sara Carolina Henriques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Carolina Henriques has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Ramos
Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
4 shared publications - Maria Manuel Donato
CIMAGO, Faculdade de Medicina, Universidade de Coimbra, 3000-548 Coimbra, Portugal
4 shared publications - Marlene Fonseca
BlueClinical Phase I Porto Portugal
4 shared publications - Olga Cardoso
CERES, Department of Chemical Engineering, Faculdade de Ciências e Tecnologia, Universidade de Coimbra, 3030-790 Coimbra, Portugal
4 shared publications Helena Gama
Research and Development, Bial‐Portela & Cª S.A., Coronado (S. Romao e S. Mamede) Portugal
3 shared publications- Luis Almeida
BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal
3 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2342
Antimicrobial Resistance to WHO-Categorised Critically Important Antimicrobials in Piglet-Derived Escherichia coli and Enterococci: A One Health Approach
Antimicrobial resistance (AMR) is a critical health issue affected by human, animal, and environmental factors within a One Health framework. Livestock production, particularly pig farming, contributes to the emergence and spread of resistant bacteria through antimicrobial use and selective pressure. This study characterized the antimicrobial resistance profiles of Escherichia coli and enterococci isolated from piglet faeces in Portugal, with emphasis on antimicrobials classified by the World Health Organization (WHO) according to their importance for human medicine. A total of 340 E. coli and 130 Enterococcus isolates were tested using disk diffusion, and the resistance frequencies were calculated at isolate level. E. coli showed high resistance to commonly used antimicrobials, including amoxicillin–clavulanic acid (67.1%) and ciprofloxacin (43.2%), a highest priority critically important antimicrobial (HPCIA). Resistance was also found to human-only drugs such as piperacillin (67.4%) and, at a lower frequency, imipenem (2.6%), a last-resort carbapenem. Multidrug resistance was detected in 61.2% of isolates. Among enterococci, E. faecium exhibited high resistance to imipenem (64.4%), while E. faecalis and other Enterococcus species showed notable resistance to ciprofloxacin. Overall, resistance crossed all WHO antimicrobial categories. This finding highlights the potential role of pig production in the dissemination of AMR across ecosystems and suggests the need for strengthened One Health surveillance and antimicrobial stewardship efforts.
- 14 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2342
Open AccessAntimicrobial Resistance to WHO-Categorised Critically Important Antimicrobials in Piglet-Derived Escherichia coli and Enterococci: A One Health Approach
Antimicrobial resistance (AMR) is a critical health issue affected by human, animal, and environmental factors within a One Health framework. Livestock production, particularly pig farming, contributes to the emergence and spread of resistant bacteria through antimicrobial use and selective pressure. This study characterized the antimicrobial resistance profiles of Escherichia coli and enterococci isolated from piglet faeces in Portugal, with emphasis on antimicrobials classified by the World Health Organization (WHO) according to their importance for human medicine. A total of 340 E. coli and 130 Enterococcus isolates were tested using disk diffusion, and the resistance frequencies were calculated at isolate level. E. coli showed high resistance to commonly used antimicrobials, including amoxicillin–clavulanic acid (67.1%) and ciprofloxacin (43.2%), a highest priority critically important antimicrobial (HPCIA). Resistance was also found to human-only drugs such as piperacillin (67.4%) and, at a lower frequency, imipenem (2.6%), a last-resort carbapenem. Multidrug resistance was detected in 61.2% of isolates. Among enterococci, E. faecium exhibited high resistance to imipenem (64.4%), while E. faecalis and other Enterococcus species showed notable resistance to ciprofloxacin. Overall, resistance crossed all WHO antimicrobial categories. This finding highlights the potential role of pig production in the dissemination of AMR across ecosystems and suggests the need for strengthened One Health surveillance and antimicrobial stewardship efforts.
- Open Access
- 14 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (6) , 1389
Fluoroquinolone Residues in Piglet Viscera and Their Impact on Intestinal Microbiota Resistance: A One Health Approach
The presence of fluoroquinolone (FQ) residues in food-producing animals has raised concerns regarding antimicrobial resistance. This study evaluated the occurrence of FQ residues in the liver and kidneys of piglets and their association with resistance patterns in Escherichia coli and Enterococcus species from piglets’ intestinal microbiota. FQ residues were found in 44% of livers and 23% of kidneys. Among 340 E. coli isolates from feces, resistance to ciprofloxacin (CIP) (43.2%) and multidrug resistance (MDR) (82.7%) were prominent. The presence of FQ in kidneys significantly increased the odds of CIP-resistant E. coli (OR = 2.94, p = 0.0013) and MDR (OR = 2.70, p = 0.0047). Enterococci (n = 130) were evenly distributed among the species E. faecalis, E. faecium, and Enterococcus spp. and presented resistance to CIP (34.6%). FQ in kidneys were associated with higher odds of CIP-resistant enterococci (OR = 3.78, p = 0.015). Interaction models revealed species-dependent responses, with Enterococcus spp. showing high resistance in the presence of FQ in kidneys (OR = 18, p = 0.006), while E. faecium exhibited lower resistance compared to E. faecalis. These findings emphasize the role of FQ residues in promoting bacterial resistance and underscore the need for the stricter regulation and routine surveillance of antimicrobial use in livestock to curb the spread of bacterial resistance to clinical drugs, and mitigate public health risks—One Health.
- 14 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (6) , 1389
Open AccessFluoroquinolone Residues in Piglet Viscera and Their Impact on Intestinal Microbiota Resistance: A One Health Approach
The presence of fluoroquinolone (FQ) residues in food-producing animals has raised concerns regarding antimicrobial resistance. This study evaluated the occurrence of FQ residues in the liver and kidneys of piglets and their association with resistance patterns in Escherichia coli and Enterococcus species from piglets’ intestinal microbiota. FQ residues were found in 44% of livers and 23% of kidneys. Among 340 E. coli isolates from feces, resistance to ciprofloxacin (CIP) (43.2%) and multidrug resistance (MDR) (82.7%) were prominent. The presence of FQ in kidneys significantly increased the odds of CIP-resistant E. coli (OR = 2.94, p = 0.0013) and MDR (OR = 2.70, p = 0.0047). Enterococci (n = 130) were evenly distributed among the species E. faecalis, E. faecium, and Enterococcus spp. and presented resistance to CIP (34.6%). FQ in kidneys were associated with higher odds of CIP-resistant enterococci (OR = 3.78, p = 0.015). Interaction models revealed species-dependent responses, with Enterococcus spp. showing high resistance in the presence of FQ in kidneys (OR = 18, p = 0.006), while E. faecium exhibited lower resistance compared to E. faecalis. These findings emphasize the role of FQ residues in promoting bacterial resistance and underscore the need for the stricter regulation and routine surveillance of antimicrobial use in livestock to curb the spread of bacterial resistance to clinical drugs, and mitigate public health risks—One Health.
- Open Access
- 11 December 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (12) , 2553
Copper and Antimicrobial Residues in the Liver and Kidney—Antimicrobial Resistance and Cu Tolerance Unrelated in Escherichia coli from Piglets’ Faeces
Antimicrobials, widely used in livestock, have induced the emergence of antimicrobial-resistant bacteria, prompting farmers to explore alternatives like copper. This study aims to determine antimicrobial residues and Cu concentrations in the liver and kidney of piglets and to investigate the correlation between Cu and antimicrobial use and the resistance to Cu and antimicrobials of Escherichia coli isolated from piglets’ faeces. Antimicrobial residues were quantified by UHPLC-ToF-MS; Cu was quantified using FAAS; microbiological methods were used for E. coli isolation, CuSO4 minimal inhibitory concentration (MIC), and antimicrobial susceptibility; and to detect genes, Real-Time PCR was used. Cu concentrations and antimicrobial residues in piglet livers and kidneys revealed no significant differences. Antimicrobial residues were detected in a significant number of livers and kidneys. While Cu concentrations in the liver were within adequate ranges, those in the kidney exceeded the recommended levels. E. coli isolates from piglet faeces exhibited high antimicrobial drug resistance (AMR), with no clear link to Cu exposure. The genes copA, pcoA, and pcoD, associated with Cu tolerance, were predominantly found in isolates with a CuSO4 MIC of 8 mM. Cu was not used excessively, suggesting that Cu did not replace antimicrobials. E. coli was mostly resistant to antimicrobials and it was not possible to demonstrate that Cu was the trigger for this resistance. There was no relationship between Cu tolerance and AMR in E. coli isolates. This study highlights the need for further research on the complex interplay between metals, antimicrobials, and bacterial resistance in livestock, impacting ‘One Health’.
- 11 December 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (12) , 2553
Open AccessCopper and Antimicrobial Residues in the Liver and Kidney—Antimicrobial Resistance and Cu Tolerance Unrelated in Escherichia coli from Piglets’ Faeces
Antimicrobials, widely used in livestock, have induced the emergence of antimicrobial-resistant bacteria, prompting farmers to explore alternatives like copper. This study aims to determine antimicrobial residues and Cu concentrations in the liver and kidney of piglets and to investigate the correlation between Cu and antimicrobial use and the resistance to Cu and antimicrobials of Escherichia coli isolated from piglets’ faeces. Antimicrobial residues were quantified by UHPLC-ToF-MS; Cu was quantified using FAAS; microbiological methods were used for E. coli isolation, CuSO4 minimal inhibitory concentration (MIC), and antimicrobial susceptibility; and to detect genes, Real-Time PCR was used. Cu concentrations and antimicrobial residues in piglet livers and kidneys revealed no significant differences. Antimicrobial residues were detected in a significant number of livers and kidneys. While Cu concentrations in the liver were within adequate ranges, those in the kidney exceeded the recommended levels. E. coli isolates from piglet faeces exhibited high antimicrobial drug resistance (AMR), with no clear link to Cu exposure. The genes copA, pcoA, and pcoD, associated with Cu tolerance, were predominantly found in isolates with a CuSO4 MIC of 8 mM. Cu was not used excessively, suggesting that Cu did not replace antimicrobials. E. coli was mostly resistant to antimicrobials and it was not possible to demonstrate that Cu was the trigger for this resistance. There was no relationship between Cu tolerance and AMR in E. coli isolates. This study highlights the need for further research on the complex interplay between metals, antimicrobials, and bacterial resistance in livestock, impacting ‘One Health’.
- Open Access
- 11 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1579
Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products
Background: When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a gatekeeping in vivo strategy to decide whether to move forward or not with a full-size pivotal study. However, due to the small study size, these studies are inarguably more sensitive to variability. Objectives: To address and mitigate the uncertainty of the conclusions of pilot studies concerning the maximum observed concentration (Cmax), the f2 factor was proposed as an alternative approach to the average bioequivalence statistical methodology. Methods: In this work, the alternative methodology is applied to pharmacokinetic data from pilot bioequivalence trials performed with pazopanib 200 mg and 400 mg. Results: Despite the small sample size, and very high intra-subject variability, the f2 factor demonstrated the potential for predicting bioequivalence. The positive results were confirmed in the full sized pivotal studies. Conclusions: In conclusion, this alternate methodology shows promise in reducing uncertainty associated with pilot studies and aiding in decisions to go forward with pivotal bioequivalence studies.
- 11 December 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1579
Open AccessUnveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products
Background: When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a gatekeeping in vivo strategy to decide whether to move forward or not with a full-size pivotal study. However, due to the small study size, these studies are inarguably more sensitive to variability. Objectives: To address and mitigate the uncertainty of the conclusions of pilot studies concerning the maximum observed concentration (Cmax), the f2 factor was proposed as an alternative approach to the average bioequivalence statistical methodology. Methods: In this work, the alternative methodology is applied to pharmacokinetic data from pilot bioequivalence trials performed with pazopanib 200 mg and 400 mg. Results: Despite the small sample size, and very high intra-subject variability, the f2 factor demonstrated the potential for predicting bioequivalence. The positive results were confirmed in the full sized pivotal studies. Conclusions: In conclusion, this alternate methodology shows promise in reducing uncertainty associated with pilot studies and aiding in decisions to go forward with pivotal bioequivalence studies.
- 6 July 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (11) , 2781-2792
Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double‐blind, randomized, placebo‐controlled study in healthy subjects
Aims: Dopamine beta‐hydroxylase (DβH) inhibitors, like zamicastat, hold promise for treating pulmonary arterial hypertension. This study aimed to validate the mechanism of action of zamicastat by studying its effect on the overdrive of the sympathetic nervous system (SNS).Methods: A single‐centre, prospective, double‐blind, randomized, placebo‐controlled, crossover study evaluated the effect of 400 mg zamicastat in 22 healthy male subjects. Cold pressor test (CPT) was performed at screening and each treatment period on Days −1 and 10. Plasma and 24 h‐urine levels of dopamine (DA), epinephrine (EPI) and norepinephrine (NE), and plasma DβH activity, were measured.Results: Compared to placebo, zamicastat showed a − 4.62 mmHg decrease in systolic blood pressure during the cold stimulus vs. rest phases on Day 10 of CPT (P = .020). Zamicastat decreased mean arterial pressure response to cold stimulus during CPT (−2.62 mmHg; P = .025). At Day 10, zamicastat significantly increased plasma DA, before CPT (12.63 ng/L; P = .040) and after CPT (19.22 ng/L; P = .001) as well as the estimated plasma EPI change from baseline after CPT (P = .040). Inhibition of plasma DβH activity ranged from 19.8% to 25.0%. At Day 10, significant reductions in 24‐h urinary excretion of EPI (P = .002) and NE (P = .001) were observed. Zamicastat Cτ geometric mean ± GSD ranged from 45.86 ± 1.46 ng/mL on Day 3 to 58.64 ± 1.52 ng/mL on Day 10, with moderate inter‐individual variability (CV: 32.6%–36.6%). Steady state was already achieved on Day 6.Conclusions: Our results demonstrated the effect of zamicastat on the overdrive sympathetic response to cold stimulus, confirming its potential as SNS modulator.
- 6 July 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (11) , 2781-2792
Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double‐blind, randomized, placebo‐controlled study in healthy subjects
Aims: Dopamine beta‐hydroxylase (DβH) inhibitors, like zamicastat, hold promise for treating pulmonary arterial hypertension. This study aimed to validate the mechanism of action of zamicastat by studying its effect on the overdrive of the sympathetic nervous system (SNS).Methods: A single‐centre, prospective, double‐blind, randomized, placebo‐controlled, crossover study evaluated the effect of 400 mg zamicastat in 22 healthy male subjects. Cold pressor test (CPT) was performed at screening and each treatment period on Days −1 and 10. Plasma and 24 h‐urine levels of dopamine (DA), epinephrine (EPI) and norepinephrine (NE), and plasma DβH activity, were measured.Results: Compared to placebo, zamicastat showed a − 4.62 mmHg decrease in systolic blood pressure during the cold stimulus vs. rest phases on Day 10 of CPT (P = .020). Zamicastat decreased mean arterial pressure response to cold stimulus during CPT (−2.62 mmHg; P = .025). At Day 10, zamicastat significantly increased plasma DA, before CPT (12.63 ng/L; P = .040) and after CPT (19.22 ng/L; P = .001) as well as the estimated plasma EPI change from baseline after CPT (P = .040). Inhibition of plasma DβH activity ranged from 19.8% to 25.0%. At Day 10, significant reductions in 24‐h urinary excretion of EPI (P = .002) and NE (P = .001) were observed. Zamicastat Cτ geometric mean ± GSD ranged from 45.86 ± 1.46 ng/mL on Day 3 to 58.64 ± 1.52 ng/mL on Day 10, with moderate inter‐individual variability (CV: 32.6%–36.6%). Steady state was already achieved on Day 6.Conclusions: Our results demonstrated the effect of zamicastat on the overdrive sympathetic response to cold stimulus, confirming its potential as SNS modulator.
- 24 June 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (11) , 1361-1372
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects
This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐day treatment with zamicastat. Since the initial dose of epoprostenol showed to be insufficiently tolerated, it was decreased to 6 ng/kg/min. Blood samples were collected to determine the metabolites of epoprostenol and concentrations of zamicastat and its metabolites. A total of 54 subjects were enrolled and data from 28 subjects were available for pharmacokinetic analysis. The epoprostenol plus zamicastat‐to‐epoprostenol geometric means ratio (GMR) and corresponding 90% confidence interval (CI) for Cav,ss and area under the plasma concentration–time curve from time 0 up to 16 h at steady state (AUC0‐16,ss) of the metabolites of epoprostenol were within the acceptance bioequivalence range (80.00%‐125.00%). The intrasubject coefficient of variation (ISCV) was below 10% for both parameters, on both metabolites. For zamicastat AUC0‐τ,ss, the zamicastat plus epoprostenol‐to‐zamicastat GMR and corresponding 90% CI were within the bioequivalence acceptance range, while for zamicastat Cmax,ss, the lower limit of the 90% CI was slightly below the acceptance range. For zamicastat metabolites, Cmax,ss and AUC0‐τ,ss and the zamicastat plus epoprostenol‐to‐zamicastat GMR were below the acceptance bioequivalence range. ISCV was between 30% and 41% for Cmax,ss and between 21% and 41% for AUC0‐τ,ss, for zamicastat and both metabolites. This study showed that the administration of zamicastat did not significantly modify the cardiovascular effects of epoprostenol and that the interactions between zamicastat and epoprostenol are not expected to be clinically relevant.
- 24 June 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (11) , 1361-1372
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects
This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐day treatment with zamicastat. Since the initial dose of epoprostenol showed to be insufficiently tolerated, it was decreased to 6 ng/kg/min. Blood samples were collected to determine the metabolites of epoprostenol and concentrations of zamicastat and its metabolites. A total of 54 subjects were enrolled and data from 28 subjects were available for pharmacokinetic analysis. The epoprostenol plus zamicastat‐to‐epoprostenol geometric means ratio (GMR) and corresponding 90% confidence interval (CI) for Cav,ss and area under the plasma concentration–time curve from time 0 up to 16 h at steady state (AUC0‐16,ss) of the metabolites of epoprostenol were within the acceptance bioequivalence range (80.00%‐125.00%). The intrasubject coefficient of variation (ISCV) was below 10% for both parameters, on both metabolites. For zamicastat AUC0‐τ,ss, the zamicastat plus epoprostenol‐to‐zamicastat GMR and corresponding 90% CI were within the bioequivalence acceptance range, while for zamicastat Cmax,ss, the lower limit of the 90% CI was slightly below the acceptance range. For zamicastat metabolites, Cmax,ss and AUC0‐τ,ss and the zamicastat plus epoprostenol‐to‐zamicastat GMR were below the acceptance bioequivalence range. ISCV was between 30% and 41% for Cmax,ss and between 21% and 41% for AUC0‐τ,ss, for zamicastat and both metabolites. This study showed that the administration of zamicastat did not significantly modify the cardiovascular effects of epoprostenol and that the interactions between zamicastat and epoprostenol are not expected to be clinically relevant.
- Open Access
- 26 December 2023
- Published by Springer Nature in Biological Trace Element Research
- Vol. 202 (10) , 4522-4530
Antibiotic Residues and Zinc Concentrations in the Livers and Kidneys of Portuguese Piglets—Relationship to Antibiotic and Zinc Resistance in Intestinal Escherichia coli
Metal ions such as zinc and copper have been used as alternatives to antibiotics, to improve animal health and growth rates in pig farming. This study aims to determine antibiotic residues and Zn concentration in piglets’ livers (n = 56) and kidneys (n = 60); and to examine the correlation between the use of Zn and antibiotics, and resistance to Zn and antibiotics of Escherichia coli isolated from piglets’ faeces (n = 60). Samples were collected from randomly selected healthy piglets (n = 60); antibiotic residues were quantified by ultra-high-performance-liquid-chromatography time-of-flight mass spectrometry (UHPLC-ToF–MS); Zn was quantified using flame atomic absorption spectrometry (FAAS); microbiological methods were used for E. coli isolation, antibiotic susceptibility, and Zn minimal inhibitory concentration; and Real-Time PCR was used for gene detection. The presence of antibiotic residues and Zn concentrations in the liver was found to be negatively correlated, whilst no significant difference was observed in the kidney. In E. coli isolated from piglet faeces considered to be susceptible or multi-drug-resistant, no significant difference was found between Zn concentrations in the liver and in the kidney, which appears to indicate that Zn accumulated in the liver and in the kidney does not promote resistance to antibiotics in E. coli. The isolates showed tolerance to Zn which would suggest that antibiotic resistance and phenotypic tolerance to Zn in these isolates are not related. The genes zitB and zntA associated to Zn tolerance, were predominantly found in the more resistant Zn isolates. The findings provide insights on how Zn use in pig production maintains antibiotic resistance and metal tolerance in bacteria, with implications for One Health.
- 26 December 2023
- Published by Springer Nature in Biological Trace Element Research
- Vol. 202 (10) , 4522-4530
Open AccessAntibiotic Residues and Zinc Concentrations in the Livers and Kidneys of Portuguese Piglets—Relationship to Antibiotic and Zinc Resistance in Intestinal Escherichia coli
Metal ions such as zinc and copper have been used as alternatives to antibiotics, to improve animal health and growth rates in pig farming. This study aims to determine antibiotic residues and Zn concentration in piglets’ livers (n = 56) and kidneys (n = 60); and to examine the correlation between the use of Zn and antibiotics, and resistance to Zn and antibiotics of Escherichia coli isolated from piglets’ faeces (n = 60). Samples were collected from randomly selected healthy piglets (n = 60); antibiotic residues were quantified by ultra-high-performance-liquid-chromatography time-of-flight mass spectrometry (UHPLC-ToF–MS); Zn was quantified using flame atomic absorption spectrometry (FAAS); microbiological methods were used for E. coli isolation, antibiotic susceptibility, and Zn minimal inhibitory concentration; and Real-Time PCR was used for gene detection. The presence of antibiotic residues and Zn concentrations in the liver was found to be negatively correlated, whilst no significant difference was observed in the kidney. In E. coli isolated from piglet faeces considered to be susceptible or multi-drug-resistant, no significant difference was found between Zn concentrations in the liver and in the kidney, which appears to indicate that Zn accumulated in the liver and in the kidney does not promote resistance to antibiotics in E. coli. The isolates showed tolerance to Zn which would suggest that antibiotic resistance and phenotypic tolerance to Zn in these isolates are not related. The genes zitB and zntA associated to Zn tolerance, were predominantly found in the more resistant Zn isolates. The findings provide insights on how Zn use in pig production maintains antibiotic resistance and metal tolerance in bacteria, with implications for One Health.
- Open Access
- 15 November 2023
- Published by Wiley
Effect of zamicastat on blood pressure and heart rate response to cold pressor test: a double-blind, randomised, placebo-controlled study in healthy subjects
Aim: Inhibitors of dopamine-β-hydroxylase (DβH), such as zamicastat, emerged as promising drugs for pulmonary arterial hypertension (PAH). This study intended to validate the mechanism of action of zamicastat by studying its effect on the overdrive of sympathetic nervous system (SNS). Methods: This was a single-centre, prospective, double-blind, randomised, placebo-controlled, crossover study, with 400 mg zamicastat, in 22 healthy male subjects. Cold pressor test (CPT) was performed at screening and each treatment period at day 1 and day 10. The concentration of dopamine (DA), epinephrine (EPI), norepinephrine (NE) in plasma and 24h-urine, and DβH activity in plasma were measured. Results: For zamicastat compared to placebo, the difference between cold stimulus and rest phases on the change from baseline to day 10 of CPT showed an estimated decrease of -4.62 mmHg for systolic blood pressure (SBP; p=0.020). Zamicastat caused a decrease of -2.62 mmHg in mean arterial pressure (MAP) response to cold stimulus during CPT (p=0.025). At day 10, zamicastat elicited a statistically significant increase of 12.63 ng/L (p=0.040) and 19.22 ng/L (p=0.001) in plasma DA, before CPT and after CPT, and a significant estimated increase in plasma EPI change from baseline after CPT (p=0.040). Inhibition of plasma DβH activity ranged from 19.8% to 25.0%. At day 10, statistically significant reductions in 24-hour urinary excretion of EPI (p=0.002) and NE (p=0.001) were observed. Conclusions: Zamicastat decreased SBP and MAP response to cold stimulus during CPT, evidencing its effect on the overdrive sympathetic response to cold stimulus.
- 15 November 2023
- Published by Wiley
Open AccessEffect of zamicastat on blood pressure and heart rate response to cold pressor test: a double-blind, randomised, placebo-controlled study in healthy subjects
Aim: Inhibitors of dopamine-β-hydroxylase (DβH), such as zamicastat, emerged as promising drugs for pulmonary arterial hypertension (PAH). This study intended to validate the mechanism of action of zamicastat by studying its effect on the overdrive of sympathetic nervous system (SNS). Methods: This was a single-centre, prospective, double-blind, randomised, placebo-controlled, crossover study, with 400 mg zamicastat, in 22 healthy male subjects. Cold pressor test (CPT) was performed at screening and each treatment period at day 1 and day 10. The concentration of dopamine (DA), epinephrine (EPI), norepinephrine (NE) in plasma and 24h-urine, and DβH activity in plasma were measured. Results: For zamicastat compared to placebo, the difference between cold stimulus and rest phases on the change from baseline to day 10 of CPT showed an estimated decrease of -4.62 mmHg for systolic blood pressure (SBP; p=0.020). Zamicastat caused a decrease of -2.62 mmHg in mean arterial pressure (MAP) response to cold stimulus during CPT (p=0.025). At day 10, zamicastat elicited a statistically significant increase of 12.63 ng/L (p=0.040) and 19.22 ng/L (p=0.001) in plasma DA, before CPT and after CPT, and a significant estimated increase in plasma EPI change from baseline after CPT (p=0.040). Inhibition of plasma DβH activity ranged from 19.8% to 25.0%. At day 10, statistically significant reductions in 24-hour urinary excretion of EPI (p=0.002) and NE (p=0.001) were observed. Conclusions: Zamicastat decreased SBP and MAP response to cold stimulus during CPT, evidencing its effect on the overdrive sympathetic response to cold stimulus.
- Open Access
- 20 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (10) , 2498
Predictive Potential of Cmax Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative ƒ2 Similarity Factor Method
Pilot bioavailability/bioequivalence (BA/BE) studies are downsized trials that can be conducted prior to the definitive pivotal trial. In these trials, 12 to 18 subjects are usually enrolled, although, in principle, a sample size is not formally calculated. In a previous work, authors recommended the use of an alternative approach to the average bioequivalence methodology to evaluate pilot studies’ data, using the geometric mean (Gmean) ƒ2 factor with a cut off of 35, which has shown to be an appropriate method to assess the potential bioequivalence for the maximum observed concentration (Cmax) metric under the assumptions of a true Test-to-Reference Geometric Mean Ratio (GMR) of 100% and an inter-occasion variability (IOV) in the range of 10% to 45%. In this work, the authors evaluated the proposed ƒ2 factor in comparison with the standard average bioequivalence in more extreme scenarios, using a true GMR of 90% or 111% for truly bioequivalent formulations, and 80% or 125% for truly bioinequivalent formulations, in order to better derive conclusions on the potential of this analysis method. Several scenarios of pilot BA/BE crossover studies were simulated through population pharmacokinetic modelling, accounting for different IOV levels. A redefined decision tree is proposed, suggesting a fixed sample size of 20 subjects for pilot studies in the case of intra-subject coefficient of variation (ISCV%) > 20% or unknown variability, and suggesting the assessment of study results through the average bioequivalence analysis, and additionally through Gmean ƒ2 factor method in the case of the 90% confidence interval (CI) for GMR is outside the regulatory acceptance bioequivalence interval of [80.00–125.00]%. Using this alternative approach, the certainty levels to proceed with pivotal studies, depending on Gmean ƒ2 values and variability scenarios tested (20–60% IOV), were assessed, which is expected to be helpful in terms of the decision to proceed with pivotal bioequivalence studies.
- 20 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (10) , 2498
Open AccessPredictive Potential of Cmax Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative ƒ2 Similarity Factor Method
Pilot bioavailability/bioequivalence (BA/BE) studies are downsized trials that can be conducted prior to the definitive pivotal trial. In these trials, 12 to 18 subjects are usually enrolled, although, in principle, a sample size is not formally calculated. In a previous work, authors recommended the use of an alternative approach to the average bioequivalence methodology to evaluate pilot studies’ data, using the geometric mean (Gmean) ƒ2 factor with a cut off of 35, which has shown to be an appropriate method to assess the potential bioequivalence for the maximum observed concentration (Cmax) metric under the assumptions of a true Test-to-Reference Geometric Mean Ratio (GMR) of 100% and an inter-occasion variability (IOV) in the range of 10% to 45%. In this work, the authors evaluated the proposed ƒ2 factor in comparison with the standard average bioequivalence in more extreme scenarios, using a true GMR of 90% or 111% for truly bioequivalent formulations, and 80% or 125% for truly bioinequivalent formulations, in order to better derive conclusions on the potential of this analysis method. Several scenarios of pilot BA/BE crossover studies were simulated through population pharmacokinetic modelling, accounting for different IOV levels. A redefined decision tree is proposed, suggesting a fixed sample size of 20 subjects for pilot studies in the case of intra-subject coefficient of variation (ISCV%) > 20% or unknown variability, and suggesting the assessment of study results through the average bioequivalence analysis, and additionally through Gmean ƒ2 factor method in the case of the 90% confidence interval (CI) for GMR is outside the regulatory acceptance bioequivalence interval of [80.00–125.00]%. Using this alternative approach, the certainty levels to proceed with pivotal studies, depending on Gmean ƒ2 values and variability scenarios tested (20–60% IOV), were assessed, which is expected to be helpful in terms of the decision to proceed with pivotal bioequivalence studies.
- Open Access
- 7 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1430
Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies
Pilot bioavailability/bioequivalence (BA/BE) studies are usually conducted and analysed similarly to pivotal studies. Their analysis and interpretation of results usually rely on the application of the average bioequivalence approach. However, due to the small study size, pilot studies are inarguably more sensitive to variability. The aim of this work is to propose alternative approaches to the average bioequivalence methodology, in a way to overcome and reduce the uncertainty on the conclusions of these studies and on the potential of test formulations. Several scenarios of pilot BA/BE crossover studies were simulated through population pharmacokinetic modelling. Each simulated BA/BE trial was analysed using the average bioequivalence approach. As alternative analyses, the centrality of the test-to-reference geometric least square means ratio (GMR), bootstrap bioequivalence analysis, and arithmetic (Amean) and geometric (Gmean) mean ƒ2 factor approaches were investigated. Methods performance was measured with a confusion matrix. The Gmean ƒ2 factor using a cut-off of 35 was the most appropriate method in the simulation conditions frame, enabling to more accurately conclude the potential of test formulations, with a reduced sample size. For simplification, a decision tree is also proposed for appropriate planning of the sample size and subsequent analysis approach to be followed in pilot BA/BE trials.
- 7 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1430
Open AccessAlternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies
Pilot bioavailability/bioequivalence (BA/BE) studies are usually conducted and analysed similarly to pivotal studies. Their analysis and interpretation of results usually rely on the application of the average bioequivalence approach. However, due to the small study size, pilot studies are inarguably more sensitive to variability. The aim of this work is to propose alternative approaches to the average bioequivalence methodology, in a way to overcome and reduce the uncertainty on the conclusions of these studies and on the potential of test formulations. Several scenarios of pilot BA/BE crossover studies were simulated through population pharmacokinetic modelling. Each simulated BA/BE trial was analysed using the average bioequivalence approach. As alternative analyses, the centrality of the test-to-reference geometric least square means ratio (GMR), bootstrap bioequivalence analysis, and arithmetic (Amean) and geometric (Gmean) mean ƒ2 factor approaches were investigated. Methods performance was measured with a confusion matrix. The Gmean ƒ2 factor using a cut-off of 35 was the most appropriate method in the simulation conditions frame, enabling to more accurately conclude the potential of test formulations, with a reduced sample size. For simplification, a decision tree is also proposed for appropriate planning of the sample size and subsequent analysis approach to be followed in pilot BA/BE trials.